Marshall Wace, LLP Affimed N.V. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.32 - $0.62 $194,336 - $376,526
607,300 New
607,300 $376,000
Q2 2022

Aug 15, 2022
SELL
$2.27 - $4.86 $506,974 - $1.09 Million
-223,337 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$3.69 - $5.65 $824,113 - $1.26 Million
223,337 New
223,337 $976,000
Q4 2021

Feb 14, 2022
SELL
$5.37 - $7.07 $958,464 - $1.26 Million
-178,485 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$5.54 - $7.51 $988,806 - $1.34 Million
178,485 New
178,485 $1.1 Million

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email